Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 16, 2007--Amgen
(NASDAQ:AMGN) will hold an analyst call at 1 p.m. Pacific Time today,
Feb. 16, 2007, to address inquiries following publication of the
interim results of the Danish Head and Neck Cancer (DAHANCA) 10 study.
Live audio of the conference call will be simultaneously broadcast
over the Internet as a webcast and will be available to members of the
news media, investors and the general public.
The webcast of the conference, as with other selected
presentations regarding developments in Amgen's business given by
management at certain investor and medical conferences, can be found
on Amgen's Web site, www.amgen.com, under Investors. Information
regarding presentation times, webcast availability, and webcast links
are noted on Amgen's Investor Relations Events Calendar. The webcast
will be archived and available for replay 72 hours after the event.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)